2017年08月 西藏奇正藏药股份有限公司 2017 年半年度报告全文 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2017年半年度报告 证券代码：002287 证券简称：奇正藏药 中国 西藏 释义 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证本半年度报告中财务报告的真实、准确、完整。 1 | 第一节 | 重要提示、目录和释义 1 | | --- | --- | | 第二节 | 公司简介和主要财务指标 4 | | 第三节 | 公司业务概要 7 | | 第四节 | 经营情况讨论与分析 10 | | 第五节 | 重要事项 20 | | 第六节 | 股份变动及股东情况 26 | | 第七节 | 优先股相关情况 29 | | 第八节 | 董事、监事、高级管理人员情况 30 | | 第九节 | 公司债相关情况 31 | | 第十节 ...

西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2016年年度报告 证券代码：002287 证券简称：奇正藏药 中国 西藏 2017年04月 西藏奇正藏药股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证年度报告中财务报告的真实、准确、完整。 本报告涉及的未来发展陈述，属于计划性事项，并不构成公司对投资者的实质承诺，投 资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差 异。 公司已在本报告中描述了公司可能面临的风险，请查阅本报告第四节之经营情况讨论与 分析中相应内容，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 406000000 为基数，向全体股东每 10 股派发现金红利 3.90 元 ...

西藏奇正藏药股份有限公司 2017 年第一季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2017-016 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2017年第一季度报告正文 证券代码：002287 证券简称：奇正藏药 中国 西藏 2017年04月 1 西藏奇正藏药股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | - ...

西藏奇正藏药股份有限公司 2016 年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2016-037 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2016年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 中国 西藏 2016年10月 1 西藏奇正藏药股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | ...

西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2016年半年度报告 证券代码：002287 证券简称：奇正藏药 中国 西藏 2016年08月 西藏奇正藏药股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 公司、本公司、母公司、股份公司、奇正藏药 | 指 | 西藏奇正藏药股份有限公司 | | 证监会 | 指 | 中国证券监督管理委员会 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 元、万元 | 指 | 人民币元、人民币万元 | | 报告期 | 指 | 2016 年 1 月 1 日至 2016 年 6 月 30 日 | | NKA | 指 | 全国性重点连锁药店 | | KA | 指 | 重点连锁药店 | 3 西藏奇正藏药股份有限公 ...

西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2015年年度报告 证券代码：002287 证券简称：奇正藏药 中国 西藏 2016年04月 西藏奇正藏药股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的未来发展陈述，属于计划性事项，并不构成公司对投资者的实质承诺，投 资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差 异。 公司已在本报告中描述了公司可能面临的风险，请查阅本报告第四节之管理层讨论与分 析中相应内容，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 406,000,000 为基数，向全体股东每 10 股派发现金红利 4.1 元 ...

西藏奇正藏药股份有限公司 2016 年第一季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2016-019 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2016年第一季度报告正文 证券代码：002287 证券简称：奇正藏药 中国 西藏 2016年04月 1 西藏奇正藏药股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | -- ...

西藏奇正藏药股份有限公司 2015 年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2015-047 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2015年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 中国 西藏 2015年10月 1 西藏奇正藏药股份有限公司 2015 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2015 年第三季度报告正文 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- ...

Financial Performance - The company's operating revenue for the first half of 2015 was ¥450,731,484.01, representing a 14.99% increase compared to ¥391,984,992.26 in the same period last year[21]. - The net profit attributable to shareholders was ¥152,260,932.59, up 16.45% from ¥130,753,946.03 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥140,839,743.83, which is a 43.86% increase from ¥97,898,960.41 year-on-year[21]. - The basic earnings per share increased by 18.75% to ¥0.38 from ¥0.32 in the same period last year[21]. - The company achieved operating revenue of 450.73 million yuan, a year-on-year increase of 14.99%[30]. - Operating profit reached 165.88 million yuan, up 42.54% compared to the previous year[30]. - The company reported a total operating income of 450.41 million yuan, representing a 15.04% increase compared to the previous year, with a gross profit margin of 78.94%[43]. - The company reported a total profit for the first half of 2015 was CNY 168,026,447.33, compared to CNY 155,084,186.87, reflecting an increase of approximately 8%[131]. - The net profit for the first half of 2015 reached CNY 151,624,650.31, representing a growth of 16% from CNY 130,260,917.06 in the previous year[132]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,771,106,384.48, a decrease of 1.16% from ¥1,791,887,126.21 at the end of the previous year[21]. - Total liabilities decreased from CNY 242,203,597.70 to CNY 227,732,205.66, a decrease of about 5.9%[123]. - The total equity decreased from CNY 1,549,683,528.51 to CNY 1,543,374,178.82, a decline of about 0.4%[124]. - The company's cash and cash equivalents at the end of the reporting period amounted to RMB 366,551,994.78, an increase from RMB 283,872,711.67 at the beginning of the period[121]. - Accounts receivable increased significantly to RMB 120,797,565.38 from RMB 12,762,939.85 at the beginning of the period[121]. - Inventory decreased to RMB 47,724,898.90 from RMB 88,113,348.40 at the beginning of the period[121]. Cash Flow - The net cash flow from operating activities was ¥246,215,603.35, which is a decrease of 9.87% compared to ¥273,167,517.52 in the same period last year[21]. - The net cash flow from operating activities was CNY 410,670,123.62, an increase from CNY 275,959,852.75 in the previous period, representing a growth of approximately 48.7%[141]. - Cash outflows from operating activities totaled CNY 158,693,192.40, up from CNY 106,977,673.78, which is an increase of about 48.3%[141]. - The net cash flow from investment activities was -CNY 89,066,425.97, a significant decline from -CNY 2,053,124.73 in the previous period[142]. - The total cash inflow from financing activities was CNY 600,000.00, while cash outflows were CNY 157,934,000.00, resulting in a net cash outflow from financing activities[139]. Investments and R&D - Research and development investment increased by 32.02% to 115.90 million yuan, indicating a commitment to innovation[32]. - The company is focusing on expanding its pharmaceutical business and strengthening its core competitive advantages, including brand, product, marketing, and R&D[45]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth[132]. - The company has a significant focus on research and development in traditional Tibetan medicine[163]. Shareholder Information - The company approved a cash dividend of 3.89 CNY per 10 shares, totaling 157,934,000 CNY distributed to shareholders[71]. - The company plans not to distribute cash dividends or issue new shares from capital reserves for the half-year period[74]. - The total number of ordinary shareholders at the end of the reporting period was 10,879[107]. - Gansu Qizheng Industrial Group Co., Ltd. holds 69.16% of the shares, totaling 280,780,000 ordinary shares[108]. - Tibet Yutuo Cultural Development Co., Ltd. holds 20.68% of the shares, totaling 83,950,000 ordinary shares[108]. Corporate Governance - The company confirmed compliance with corporate governance regulations and no discrepancies were noted[78]. - The company has made commitments to avoid competition with its shareholders and protect minority shareholders' rights[97]. - The company emphasizes the importance of fair pricing in related party transactions to protect the interests of minority shareholders[99]. - The company has not undergone any penalties or rectifications during the reporting period[101]. Miscellaneous - The company has not made any external investments during the reporting period[47]. - There were no major litigation or arbitration matters during the reporting period[79]. - The company did not engage in any asset acquisitions or sales during the reporting period[81][82]. - The company has not identified any issues or other circumstances regarding the use and disclosure of raised funds[64]. - The company has confirmed its ability to continue operations for at least 12 months from the end of the reporting period[165].

Financial Performance - The company's operating revenue for Q1 2015 was ¥176,896,091.46, representing a 19.66% increase compared to ¥147,835,513.83 in the same period last year[9] - Net profit attributable to shareholders was ¥55,534,375.83, up 11.58% from ¥49,771,350.30 year-on-year[9] - The net profit after deducting non-recurring gains and losses increased by 45.18%, reaching ¥52,305,455.41 compared to ¥36,028,591.81 in the previous year[9] - Basic and diluted earnings per share were both ¥0.14, reflecting a 16.67% increase from ¥0.12 in the previous year[9] - The net profit attributable to shareholders for the first half of 2015 is expected to range from CNY 13,075.39 million to CNY 16,998.01 million, reflecting a change of 0.00% to 30.00% compared to the same period in 2014[21] - The main reason for the profit change is attributed to the continuous and stable growth in operating revenue[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,811,363,061.18, a 1.09% increase from the previous year's end[9] - Net assets attributable to shareholders increased by 3.69% to ¥1,559,714,480.71 from ¥1,504,180,104.88 at the end of the previous year[9] - Accounts receivable increased by 897.65% to ¥127,330,028.99 due to growth in pharmaceutical sales[17] - Interest receivable rose by 107.10% to ¥448,467.81 from increased accrued interest on deposits[17] - Other receivables increased by 116.63% to ¥23,096,179.99 due to higher advances[17] Cash Flow - The net cash flow from operating activities decreased by 28.84% to ¥83,670,052.61 from ¥117,576,882.27 in the same period last year[9] - Cash flow from investing activities showed a net outflow of ¥82,189,382.90, a 429.74% increase due to purchases of bank wealth management products[17] - Net cash and cash equivalents decreased by 98.55% to ¥1,480,669.71 as cash outflows from investment activities increased[17] Expenses - Development expenses reached ¥1,860,000.00, marking a 100% increase as new project development costs were incurred[17] - Operating tax and surcharges increased by 74.89% to ¥1,954,249.09 due to higher VAT payable[17] - Income tax expenses decreased by 39.31% to ¥5,892,393.10 due to tax incentives for the parent company and subsidiaries[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,747[12] - The largest shareholder, Gansu Qizheng Industrial Group Co., Ltd., held 69.22% of the shares, totaling 281,050,000 shares[13] - The company received government subsidies amounting to ¥1,547,671.43 during the reporting period[10] Related Party Transactions and Commitments - The company has committed to ensuring that related party transactions are conducted fairly and in accordance with market principles to protect the interests of minority shareholders[20] - The commitments made by the actual controller of the company, Lei Jufang, to avoid any misuse of company funds remain effective and irrevocable during the listing period[20] Investment Activities - There were no securities investments or holdings in other listed companies during the reporting period[22][23]